Sat, Oct 25, 2014, 10:23 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

POZEN Inc. Message Board

  • jrdelane jrdelane Aug 7, 2014 7:44 AM Flag

    Record Quarterly VIMOVO® Sales Generate $5.4 Million Royalty

    Corporate Highlights

    POZEN reported net income of $3.0 million for the second quarter and, based upon current projections, expects to be profitable for the year.
    Royalty revenue from VIMOVO® (naproxen / esomeprazole magnesium) for Q2 2014 was $5.4 million, an increase of $0.9 million over the prior quarter and $3.8 million over Q2 of 2013.
    POZEN announced that the resubmission of the New Drug Application (NDA) for PA8140/PA32540 was submitted to the U.S. Food and Drug Administration (FDA), and has been accepted for review. The FDA indicated the NDA would be treated as a Class 2 resubmission with a new user fee goal date of December 30, 2014.
    POZEN remains committed to controlling expenses and recorded an expense reduction of $1.2 million compared to Q2 2013. As part of the expense control, the Company has reduced its R&D staff and other costs and will continue to reduce costs not required to support the ongoing business activities.

    Sentiment: Buy

 
POZN
8.750.00(0.00%)Oct 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.